EUVIMEDEUVIMED entdecken
Crossref

Unique Liquid Chromatography Technique for Determining a New Selective PPARα Modulator Drug (Pemafibrate) in the Tablet Dosage Form, Robustness by Design Expert in the Light of Quality by Design

Fei Han, Yankun Yang, Zhonghu Bai, Rathnakar Nathi iD, Naresh Konduru iD

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Fei Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Biotechnology and Key Laboratory of Industrial Biotechnology of Ministry of Education, Jiangnan University, Wuxi, China. Hauptthemen laut MEDLINE: Benzoxazoles, Butyrates, PPAR alpha. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This research study presents a precise, accurate, and linear liquid‐chromatography method for the determination of pemafibrate in tablet dosage forms, despite the presence of a high volume of excipients. Various challenges were addressed through experimental approaches and evidence‐based solutions. The method employs a suitable stationary phase, X‐Bridge C 18 (150 × 4.6 mm, 3.5 μm), and an appropriate isocratic program. Key parameters include a flow rate of 1.0 mL/min, a column temperature of 40°C, an injection volume of 10 μL, and a runtime of 15 min. The wavelength was set at 210 nm because of its high response. Mobile phase optimization, based on experimental results, consists of 0.1% H 3 PO 4 buffer and acetonitrile in a 40:60 v/v ratio. The method has been validated according to ICH Q2 (R2) and Ch. P guidelines, achieving a recovery rate of 99.1% to 100.5% at levels of 50%, 100%, and 150%. Linearity was demonstrated from 25% to 300% concentration levels, with a correlation coefficient ( r 2 ) value of 1.000. Precision results showed %RSD values of 1.0 and 1.1. Forced degradation studies indicated sensitivity to acid hydrolysis stress conditions and stability under physical stress conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazolesButyratesPPAR alphaTabletsLinear ModelsReproducibility of ResultsLimit of DetectionChromatography, LiquidChromatography, High Pressure Liquid

Stichwörter der Autor:innen

LC methodRP‐HPLCforced degradation studiespemafibrate drug productselective PPAR alpha modulator (SPPARMα)

Substanzen

TabletsBenzoxazoles(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidButyratesPPAR alpha

Autor:innen und Institutionen

  • School of Biotechnology and Key Laboratory of Industrial Biotechnology of Ministry of Education, Jiangnan University, Wuxi, China.
  • National Engineering Research Center of Cereal Fermentation and Food Biomanufacturing, Jiangnan University, Wuxi, China.
  • Jiangsu Provincial Engineering Research Center for Bioactive Product Processing, Jiangnan University, Wuxi, China.
  • R&D Department, Shanghai Aurora Biotechnology Co., Ltd, Shanghai, China.
  • School of Biotechnology, Zhengzhou University of Technology, Zhengzhou, China.
  • Quality Control Department, Aarkish Pharmaceuticals NJ INC, Fairfield, New Jersey, USA.

ORCID-Profile: Rathnakar Nathi, Naresh Konduru

Zitieren

APA

Han, F., Yang, Y., Bai, Z., Nathi, R., & Konduru, N. (2025). Unique Liquid Chromatography Technique for Determining a New Selective PPARα Modulator Drug (Pemafibrate) in the Tablet Dosage Form, Robustness by Design Expert in the Light of Quality by Design. Biomedical Chromatography. https://doi.org/10.1002/bmc.70006

Vancouver

Han F, Yang Y, Bai Z, Nathi R, Konduru N. Unique Liquid Chromatography Technique for Determining a New Selective PPARα Modulator Drug (Pemafibrate) in the Tablet Dosage Form, Robustness by Design Expert in the Light of Quality by Design. Biomedical Chromatography. 2025. doi:10.1002/bmc.70006

BibTeX
@article{Han2025,
  author = {Han, Fei and Yang, Yankun and Bai, Zhonghu and Nathi, Rathnakar and Konduru, Naresh},
  title = {Unique Liquid Chromatography Technique for Determining a New Selective PPARα Modulator Drug (Pemafibrate) in the Tablet Dosage Form, Robustness by Design Expert in the Light of Quality by Design},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70006}
}
Kostenlos starten →